We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




First Prostate Cancer Patient in France Treated with New Radiotherapy

By HospiMedica International staff writers
Posted on 22 Jan 2009
A 60-year-old prostate cancer patient has become the first person in France to be treated using the newest intensity-modulated radiotherapy technology.

The technology, called RapidArc, was developed by Varian Medical Systems (Palo Alto, CA, USA) for fast and precise forms of IMRT. More...
Each of his treatments at the CRLC Val Darrell-Paul Lamarque (Montpellier, France), took just 75 seconds, several times faster than conventional IMRT treatments.

Dr. Pascal Fenoglietto, the hospital's chief medical physicist for scientific projects, presented the case to colleagues at the annual meeting of the French Society of Radiation Oncologists (SFRO) in Paris from November 12-14, 2008. "The treatments went extremely well and the patient was very pleased because compared to conventional IMRT it was three times quicker,” Dr. Fenoglietto said. "We are now able to use the time we save on treatment delivery to take more images and increase the quality of our care.”

"The radiation therapists were also very pleased because it is a simpler treatment for them to deliver,” added Prof. Jean-Bernard Dubois, head of the radiation oncology department and managing director of the hospital.

With RapidArc, Varian's Clinac medical linear accelerator can target radiation beams at a tumor while making one continuous rotation around the patient. Conventional IMRT treatments are slower and more difficult for radiotherapy radiographers because they target tumors using a complicated sequence of fixed beams from multiple angles.

RapidArc technology allows more control to conform the dose more closely to the size, shape, and location of the tumor. Faster treatment also contributes to precision by reducing the time for motion within the anatomy, and laboratory studies suggest that faster dose delivery kills cancer cells more effectively. "With this technology we have the opportunity to improve outcomes while offering more patients greater access to advanced care,” Dr. Fenoglietto said. "We're excited to be the first hospital in France and the fourth in Europe to offer this treatment to patients.”

The hospital, one of the seven members of Varian's RapidArc Council of pioneering centers that helped develop the clinical use of the new treatment technology, performed the treatment on one of the four Varian linear accelerators in the department using French-language treatment planning and oncology information-management software. More than 700 patients have been treated with IMRT at the comprehensive cancer center since its introduction in 2001 and there are plans to replace all conventional IMRT treatments for tumors in the pelvic region with RapidArc treatments.

According to radiation oncologist Dr. Carmen Llacer Moscardo, "Pelvic cases can take between 12 and 14 minutes to treat with IMRT but we can now do them in under two minutes with one arc or, if clinically relevant, about three minutes with two arcs around the patient with RapidArc. If we do this, there is less possibility for the patient to move and we reduce the chance of internal motion playing a part, as there tends to be a lot of motion in the pelvic region. Also, fast treatments reduce the possibility of inaccuracy and increase patient comfort.”

RapidArc delivers a volumetric intensity-modulated radiation therapy treatment in a single or multiple arcs of the treatment machine around the patient and makes it possible to provide sophisticated image-guided IMRT two to eight times faster than is possible with conventional IMRT. Radiotherapy studies correlate the ability to spare more healthy tissue with reduced complications and better outcomes.

Related Links:

Varian Medical Systems
CRLC Val Darrell-Paul Lamarque



Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Multi-Chamber Washer-Disinfector
WD 390
Hybrid Arch Device
Neo EDE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.